메뉴 건너뛰기




Volumn 12, Issue 40, 2006, Pages 6522-6526

Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer

Author keywords

CDDP; Chemotherapy; CPT 11; Gastric cancer; Protracted Irinotecan

Indexed keywords

BILIRUBIN; CISPLATIN; FLUOROURACIL; GRANISETRON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE;

EID: 33750991893     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i40.6522     Document Type: Article
Times cited : (5)

References (25)
  • 1
    • 0028055214 scopus 로고
    • Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer
    • North Central Cancer Treatment Group
    • Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA, Krook JE, Mailliard JA, Tschetter LK. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol 1994; 12: 412-416
    • (1994) J Clin Oncol , vol.12 , pp. 412-416
    • Cullinan, S.A.1    Moertel, C.G.2    Wieand, H.S.3    O'Connell, M.J.4    Poon, M.A.5    Krook, J.E.6    Mailliard, J.A.7    Tschetter, L.K.8
  • 2
    • 0027198871 scopus 로고
    • A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer
    • Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813-3818
    • (1993) Cancer , vol.71 , pp. 3813-3818
    • Kim, N.K.1    Park, Y.S.2    Heo, D.S.3    Suh, C.4    Kim, S.Y.5    Park, K.C.6    Kang, Y.K.7    Shin, D.B.8    Kim, H.T.9    Kim, H.J.10
  • 3
    • 18744373000 scopus 로고    scopus 로고
    • Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)
    • Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21: 54-59
    • (2003) J Clin Oncol , vol.21 , pp. 54-59
    • Ohtsu, A.1    Shimada, Y.2    Shirao, K.3    Boku, N.4    Hyodo, I.5    Saito, H.6    Yamamichi, N.7    Miyata, Y.8    Ikeda, N.9    Yamamoto, S.10    Fukuda, H.11    Yoshida, S.12
  • 4
    • 18544367472 scopus 로고    scopus 로고
    • Current status and future prospects of chemotherapy for metastatic gastric cancer: A review
    • Ohtsu A. Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer 2005; 8: 95-102
    • (2005) Gastric Cancer , vol.8 , pp. 95-102
    • Ohtsu, A.1
  • 8
    • 0032919992 scopus 로고    scopus 로고
    • Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer
    • Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17: 319-323
    • (1999) J Clin Oncol , vol.17 , pp. 319-323
    • Boku, N.1    Ohtsu, A.2    Shimada, Y.3    Shirao, K.4    Seki, S.5    Saito, H.6    Sakata, Y.7    Hyodo, I.8
  • 9
    • 0036468440 scopus 로고    scopus 로고
    • CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: Results of a phase II study
    • Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002; 94: 641-646
    • (2002) Cancer , vol.94 , pp. 641-646
    • Ajani, J.A.1    Baker, J.2    Pisters, P.W.3    Ho, L.4    Mansfield, P.F.5    Feig, B.W.6    Charnsangavej, C.7
  • 10
    • 0037256399 scopus 로고    scopus 로고
    • Pharmacokinetic study of two infusion schedules of irinotecan combined with cisplatin in patients with advanced gastric cancer
    • Fujitani K, Tsujinaka T, Hirao M. Pharmacokinetic study of two infusion schedules of irinotecan combined with cisplatin in patients with advanced gastric cancer. Oncology 2003; 64: 111-115
    • (2003) Oncology , vol.64 , pp. 111-115
    • Fujitani, K.1    Tsujinaka, T.2    Hirao, M.3
  • 14
    • 0028158012 scopus 로고
    • Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks
    • Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen TL, Rock MK, Donehower RC. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994; 54: 427-436
    • (1994) Cancer Res , vol.54 , pp. 427-436
    • Rowinsky, E.K.1    Grochow, L.B.2    Ettinger, D.S.3    Sartorius, S.E.4    Lubejko, B.G.5    Chen, T.L.6    Rock, M.K.7    Donehower, R.C.8
  • 15
    • 0028854897 scopus 로고
    • Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients
    • Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210-221
    • (1995) J Clin Oncol , vol.13 , pp. 210-221
    • Abigerges, D.1    Chabot, G.G.2    Armand, J.P.3    Herait, P.4    Gouyette, A.5    Gandia, D.6
  • 16
    • 0028843263 scopus 로고
    • Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11
    • Sasaki Y, Yoshida Y, Sudoh K, Hakusui H, Fujii H, Ohtsu T, Wakita H, Igarashi T, Itoh K. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 1995; 86: 111-116
    • (1995) Jpn J Cancer Res , vol.86 , pp. 111-116
    • Sasaki, Y.1    Yoshida, Y.2    Sudoh, K.3    Hakusui, H.4    Fujii, H.5    Ohtsu, T.6    Wakita, H.7    Igarashi, T.8    Itoh, K.9
  • 20
    • 0029948891 scopus 로고    scopus 로고
    • Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions
    • Kurihara N, Kubota T, Hoshiya Y, Otani Y, Ando N, Kumai K, Kitajima M. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions. J Surg Oncol 1996; 62: 135-138
    • (1996) J Surg Oncol , vol.62 , pp. 135-138
    • Kurihara, N.1    Kubota, T.2    Hoshiya, Y.3    Otani, Y.4    Ando, N.5    Kumai, K.6    Kitajima, M.7
  • 23
    • 0035035706 scopus 로고    scopus 로고
    • Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer
    • Sato A, Kurihara M, Matsukawa M, Shimada K, Yamazaki T, Nakamachi M, Koda T. Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer. Cancer Chemother Pharmacol 2001; 47: 380-384
    • (2001) Cancer Chemother Pharmacol , vol.47 , pp. 380-384
    • Sato, A.1    Kurihara, M.2    Matsukawa, M.3    Shimada, K.4    Yamazaki, T.5    Nakamachi, M.6    Koda, T.7
  • 25
    • 0642283904 scopus 로고    scopus 로고
    • Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil
    • Shimada S, Yagi Y, Kuramoto M, Aoki N, Ogawa M. Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil. Oncol Rep 2003; 10: 687-691
    • (2003) Oncol Rep , vol.10 , pp. 687-691
    • Shimada, S.1    Yagi, Y.2    Kuramoto, M.3    Aoki, N.4    Ogawa, M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.